Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials

OP0169 Sarilumab for the treatment of ankylosing spondylitis: Results of a phase 2, randomized. Double-blind, placebo-controlled, international study (align)

(2014) J. Sieper et al.   ANNALS OF THE RHEUMATIC DISEASES

Management of Comorbidities in Ankylosing Spondylitis

(2012) James Rosenbaum et al.   AMERICAN JOURNAL OF THE MEDICAL SCIENCES

Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study

(2011) I.-H. Song et al.   ANNALS OF THE RHEUMATIC DISEASES

2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis

(2011) J. Braun et al.   ANNALS OF THE RHEUMATIC DISEASES

Ankylosing Spondylitis Refractory to Tumor Necrosis Factor Blockade Responds to Tocilizumab

(2011) J.-D. COHEN et al.   JOURNAL OF RHEUMATOLOGY

Tocilizumab, a humanized anti-interleukin-6 receptor antibody, ameliorated clinical symptoms and MRI findings of a patient with ankylosing spondylitis

(2011) Yoshihito Shima et al.   Modern Rheumatology

Integrated safety in tocilizumab clinical trials

(2011) Michael H Schiff et al.   ARTHRITIS RESEARCH & THERAPY

Mixed response to tocilizumab for ankylosing spondylitis

(2010) J. C. Henes et al.   ANNALS OF THE RHEUMATIC DISEASES

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

(2010) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab in a patient with ankylosing spondylitis and Crohn's disease refractory to TNF antagonists

(2010) Laure Brulhart et al.   JOINT BONE SPINE

Pathogenesis of ankylosing spondylitis

(2010) Lai-Shan Tam et al.   Nature Reviews Rheumatology

Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study

(2009) G. Jones et al.   ANNALS OF THE RHEUMATIC DISEASES

Effectiveness, Safety, and Predictors of Good Clinical Response in 1250 Patients Treated with Adalimumab for Active Ankylosing Spondylitis

(2009) M. RUDWALEIT et al.   JOURNAL OF RHEUMATOLOGY

Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial

(2008) D van der Heijde et al.   ANNALS OF THE RHEUMATIC DISEASES

IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial

(2008) P. Emery et al.   ANNALS OF THE RHEUMATIC DISEASES

Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis

(2008) S Visvanathan et al.   ANNALS OF THE RHEUMATIC DISEASES

Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

(2008) Mark C. Genovese et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial

(2008) Robert D. Inman et al.   ARTHRITIS AND RHEUMATISM

Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis

(2008) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial

(2008) Josef S Smolen et al.   LANCET